Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®
EP. 1: Current and Emerging Trends in Breast Cancer: HER2 + and HER2-Low An OncLive® Scientific Interchange and Workshop
This article provides a summary of data on treatment approaches for HER2-positive breast cancer presented at conferences in 2021 and offers a review of how findings may affect clinical approaches to escalating or de-escalating therapy in patients with early-stage disease, optimally sequencing HER2-targeted therapy in patients with metastatic breast cancer, and selecting HER2-targeted agents based on the burden of CNS disease.
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC